KYOWA KIRIN CO., LTD.
- Country
- ๐ฏ๐ตJapan
- Ownership
- Public, Subsidiary
- Established
- 1949-07-01
- Employees
- 5.9K
- Market Cap
- -
- Website
- http://www.kyowa-kirin.co.jp
A Phase 3 Clinical Study of KW-3357 in Patients With DIC
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT01384409
An Open-label Study of KW-3357
- Conditions
- Interventions
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 221
- Registration Number
- NCT01384903
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Registration Number
- NCT01377376
A Study of LY2523355 in Patients With Solid Cancer
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT01358019
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT01340482
- Locations
- ๐บ๐ธ
University of California, San Francisco Medical Center, San Francisco, California, United States
๐บ๐ธClinical Research Center, Indiana University School of Medicine, Indianapolis, Indiana, United States
๐บ๐ธYale University School of Medicine, New Haven, Connecticut, United States
A Comparative Study of KW-2246
- Conditions
- Interventions
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01326689
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT01279291
- Locations
- ๐บ๐ธ
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธCedar Sinai-Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of ARQ 197 in Combination With Erlotinib
- Conditions
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT01251796
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
- Conditions
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT01226472
- Locations
- ๐บ๐ธ
Stanford University, Stanford, California, United States
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT01199367
- Locations
- ๐บ๐ธ
Associates in Hematology-Oncology, Los Angeles, California, United States
๐บ๐ธClinical Oncology Associates, Farmington Hills, Michigan, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States